Zai Lab Ltd. 2026 Q2 10-Q Filing Summary
Business Context and Reporting Period
Zai Lab Limited (Zai Lab) is a commercial-stage biopharmaceutical company focused on oncology, immunology, neuroscience, and infectious diseases, with principal operations in Greater China and the United States. This report covers the quarterly period ended June 30, 2026. The company operates as a single segment and continues to incur net losses while advancing its commercial portfolio and R&D pipeline.
Key Financial Metrics
| Metric | Q2 2026 | Q2 2025 | 6 Months 2026 | 6 Months 2025 |
|---|---|---|---|---|
| Total Revenue | $106.3M | $110.0M | $205.9M | $216.5M |
| Net Loss | ($50.8M) | ($40.7M) | ($101.8M) | ($89.2M) |
| Loss Per Share (Basic/Diluted) | ($0.05) | ($0.04) | ($0.09) | ($0.08) |
| Operating Cash Flow | ($75.3M) (6mo) | ($92.7M) (6mo) | N/A | N/A |
| Cash & Equivalents | $607.5M | $679.6M | N/A | N/A |
| Short-Term Debt | $238.1M | $204.5M | N/A | N/A |
| Total Assets | $1.07B | $1.17B | N/A | N/A |
Note: Cash and cash equivalents exclude restricted cash of $100.0M and short-term investments of $10.0M.
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased 3% in Q2 2026 compared to Q2 2025. Net product revenue fell 3% to $105.8M.
- ZEJULA: Revenue dropped 22% to $32.1M due to shifts in hospital utilization following volume-based procurement for generic olaparib.
- VYVGART: Revenue declined 10% to $23.9M, primarily due to pricing adjustments related to National Reimbursement Drug List (NRDL) renewal.
- Offsetting Growth: XACDURO revenue surged 72% to $8.0M (supply constrained), and NUZYRA rose 20% to $17.1M due to expanded market coverage.
- Increased Expenses:
- R&D: Increased 22% to $61.8M, driven by a $15.0M increase in licensing fees (milestone payments) and pre-clinical program costs.
- SG&A: Increased 3% to $72.9M, reflecting continued commercialization efforts.
- Foreign Currency Gains: Significant non-operating gain of $15.1M in Q2 2026 (vs. $2.8M in Q2 2025) due to RMB appreciation against the USD.
- Inventory Write-downs: Recorded $6.1M in inventory write-downs for the six months ended June 30, 2026, primarily related to VYVGART Hytrulo.
Guidance, Outlook, and Risks
- Commercial Launches: Launched KarXT in mainland China in June 2026 for schizophrenia; preparing for NRDL inclusion in 2027. Received NMPA approval for TIVDAK (cervical cancer) in June 2026.
- Pipeline Progress:
- Zoci (DLL3-Targeting ADC): Presented positive data for SCLC with brain metastases (53.7% intracranial response rate). Received FDA Fast Track Designation for extrapulmonary NECs and EMA/FDA Orphan Drug Designations.
- Elegrobart: Partner Viridian announced positive Phase 3 data for chronic Thyroid Eye Disease (TED).
- Liquidity: Management expects cash and cash equivalents ($717.5M including restricted cash and short-term investments) to fund operations for at least the next 12 months. The company has access to approximately $320.0M in debt facilities, with $238.1M currently drawn.
- Risks: Key risks include regulatory approval uncertainties, reliance on third-party manufacturers, currency exchange fluctuations, and the impact of Chinese government policies (e.g., NRDL pricing, volume-based procurement). The company faces potential future milestone payments of up to $3.08 billion in sales-based milestones and $1.06 billion in development/regulatory milestones.
Investor Verification Checklist
- Revenue Sustainability: Verify the long-term impact of volume-based procurement on ZEJULA and NRDL pricing on VYVGART.
- Inventory Valuation: Review the $6.1M inventory write-down rationale and potential future write-downs for VYVGART Hytrulo.
- R&D Milestone Obligations: Assess the cash flow impact of the $15.0M licensing fees incurred in Q2 and the total potential future milestone liability of over $4 billion.
- Debt Covenants: Confirm compliance with short-term debt covenants given the increase in debt to $238.1M.
- KarXT Commercialization: Monitor early sales data for KarXT post-launch and the timeline for NRDL inclusion.